Anticancer efficacies of doxorubicin,verapamil and quercetin on FM3A cells under hyperthermic temperature |
| |
Authors: | Email author" target="_blank">Jeong?Beom?LeeEmail author Jun?Sang?Bae Jeong?Hwan?Choi Joo?Hyen?Ham Young?Ki?Min Hun?Mo?Yang Timothy?Othman Kazuhiro?Shimizu |
| |
Institution: | (1) Department of Physiology, College of Medicine, Soonchunhyang University, 330-090 Cheonan, Korea;(2) Department of Pediatrics, Division of Pediatric Endocrinology, School of Medicine, Yale University, 333 Cedar Street, PO Box 208064, 06520-8064 New Heaven, CT, USA;(3) Department of Dermatology, School of Medicine, Nagasaki University, 852-8501 Nagasaki, Japan |
| |
Abstract: | Hyperthermia (HT) in combination with anticancer drugs (ACDs) had proven to more efficacious in various cancers, although
efficacies vary according to chemotherapeutic compounds and cancer types. Presently there are few data that compares anticancer
efficacies among ACDs under hyperthermic conditions. Therefore, we selected three commonly used ACDs (quercetin, verapamil
and doxorubicin) and compared their antitumor effects when each was treated with 43°C HT exposure. Firstly, FM3A, a murine
breast cancer cell line, was treated with each ACD for 1 h followed by 43°C exposure for additional 1 h, and examined the
effects of: 1) each drug, 2) 43°C HT exposure, and 3) the combination of each drug and 43°C HT exposure for 1, 6 and 24 h.
The determined overall effects on FM3A cells were arrested cell proliferation, clonogenic efficiency and apoptosis. Pre-treatment
of FM3A cells to each ACD followed by 43°C HT exposure produced greater antitumor effects including suppressed cell proliferation,
reduced clonogenic efficiency and increased apoptotic cell death, compared to ACD treatment or HT exposure alone. Apoptotic
cell death occurred in a time-dependent manner. Among the ACDs, antitumor efficacies varied in the order of doxorubicin >
verapamil > quercetin. It was concluded that heat exposure during ACD treatment of caner cells may be an important factor
to get a better antitumor benefit, even though this benefit may differ from one drug to another. |
| |
Keywords: | hyperthermia FM3A cells anticancer drugs apoptosis cancer cytotoxicity |
本文献已被 SpringerLink 等数据库收录! |
|